Inhibikase Therapeutics, Inc. SEC filings IKT
Inhibikase Therapeutics, Inc. has 368 filings in SEC EDGAR's recent list, going back to Aug 31, 2018. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 20, 2026 (officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jun 27, 2025 | — |
| CORRESP | Letter to the SEC | Jun 25, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 25, 2025 | — |
| EFFECT | Filing | Jan 16, 2025 | — |
| CORRESP | Letter to the SEC | Jan 14, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 14, 2025 | — |
| EFFECT | Filing | Dec 5, 2024 | — |
| CORRESP | Letter to the SEC | Dec 3, 2024 | — |
| SC 14F1 | Filing | Oct 11, 2024 | — |
| EFFECT | Filing | Jun 26, 2024 | — |
| CORRESP | Letter to the SEC | Jun 24, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 21, 2024 | — |
| D | Filing | Jun 4, 2024 | — |
| RW | Filing | May 15, 2024 | — |
| EFFECT | Filing | Apr 4, 2023 | — |
| EFFECT | Filing | Feb 7, 2023 | — |
| D | Filing | Feb 7, 2023 | — |
| UPLOAD | Letter from the SEC | Feb 3, 2023 | — |
| CORRESP | Letter to the SEC | Feb 3, 2023 | — |
| DEFR14A | Filing | Jun 22, 2022 | — |
| EFFECT | Filing | Feb 11, 2022 | — |
| CORRESP | Letter to the SEC | Feb 9, 2022 | — |
| UPLOAD | Letter from the SEC | Feb 9, 2022 | — |
| EFFECT | Filing | Jun 15, 2021 | — |
| CORRESP | Letter to the SEC | Jun 11, 2021 | — |
| CORRESP | Letter to the SEC | Jun 11, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 3, 2021 | — |
| DRS | Filing | Jun 2, 2021 | — |
| EFFECT | Filing | Dec 22, 2020 | — |
| CORRESP | Letter to the SEC | Dec 17, 2020 | — |
| CORRESP | Letter to the SEC | Dec 17, 2020 | — |
| CORRESP | Letter to the SEC | Nov 12, 2020 | — |
| CORRESP | Letter to the SEC | Nov 12, 2020 | — |
| CORRESP | Letter to the SEC | Nov 6, 2020 | — |
| CORRESP | Letter to the SEC | Nov 6, 2020 | — |
| CORRESP | Letter to the SEC | Oct 30, 2020 | — |
| CORRESP | Letter to the SEC | Oct 30, 2020 | — |
| CERT | Filing | Oct 29, 2020 | — |
| 8-A12B | Filing | Oct 29, 2020 | — |
| CORRESP | Letter to the SEC | Oct 27, 2020 | — |
| CORRESP | Letter to the SEC | Oct 27, 2020 | — |
| CORRESP | Letter to the SEC | Sep 29, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 23, 2020 | — |
| CORRESP | Letter to the SEC | Sep 22, 2020 | — |
| CORRESP | Letter to the SEC | Sep 15, 2020 | — |
| UPLOAD | Letter from the SEC | Aug 14, 2020 | — |
| CORRESP | Letter to the SEC | Jul 23, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 31, 2018 | — |
| DRS/A | Filing | Oct 16, 2018 | — |
| DRSLTR | Filing | Oct 15, 2018 | — |
| UPLOAD | Letter from the SEC | Oct 10, 2018 | — |
| UPLOAD | Letter from the SEC | Sep 7, 2018 | — |
| DRSLTR | Filing | Sep 6, 2018 | — |
| DRS | Filing | Aug 31, 2018 | — |
Showing 54 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IKT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wilmington, DE
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1750149
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.